Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Completed · Not applicable · Has a placebo group

Conditions studied: Tobacco Dependence

In brief

The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that has been shown to help people quit smoking. This study was trying to evaluate whether varenicline would change the response to smoking and the desire for cigarettes when compared to an inactive placebo control. This was not a quit smoking treatment study, and participants were not asked or required to stop smoking while in this study.

Key facts

Study ID

NCT00747643

Run by

H. Lee Moffitt Cancer Center and Research Institute

People needed

163

Starts

2008-09-01

Expected to finish

2010-08-01

Last updated by the study team

2013-12-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-60 years of age
• Smoke at least 15 cigarettes daily
• Expired-air carbon monoxide (CO) > 10 ppm
• Medically eligible to receive Varenicline.

You may not qualify if…

• Patients who are pregnant or lactating
• Who show evidence of renal dysfunction (BUN > 25 mg/dL, or creatinine > 1.3 mg/dL)
• Are using other smoking cessation medications
• Have current psychiatric disorders (i.e. major depression, manic depression, and/or psychotic episodes) as determined by the Structured Clinical Interview for DSM Disorders (SCID) (First et al., 1996), will be excluded

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.